4CNI image
Deposition Date 2014-01-22
Release Date 2014-04-30
Last Version Date 2024-10-23
Entry Detail
PDB ID:
4CNI
Keywords:
IMMUNE SYSTEM
Title:
Crystal structure of the Fab portion of Olokizumab in complex with IL- 6
Biological Source:
Source Organism:
HOMO SAPIENS (Taxon ID: 9606)
Host Organism:
CRICETULUS GRISEUS
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.20 Å
R-Value Free:
0.21
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 6
4CNI validation report
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:OLOKIZUMAB HEAVY CHAIN, FAB PORTION
Chain IDs:A, E (auth: H)
Chain Length:220
Number of Molecules:2
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Molecule:OLOKIZUMAB LIGHT CHAIN, FAB PORTION
Chain IDs:B, F (auth: L)
Chain Length:214
Number of Molecules:2
Biological Source:HOMO SAPIENS
Protein Blast
Polymer Type:polypeptide(L)
Molecule:INTERLEUKIN-6
Gene (Uniprot):IL6
Chain IDs:C, D
Chain Length:171
Number of Molecules:2
Biological Source:HOMO SAPIENS
UniProt ID:P05231 Pfam ID:PF00489
Ligand Molecules
SO4
TAM
Primary Citation
Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing Gp130-Signaling.
Mabs 6 773 ? (2014)
PMID: 24670876 DOI: 10.4161/MABS.28612

Abstact

Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
4CNI